Rejected at 8:28 p.m. Oct, 31, 2023 ] by dollajas
Author: dopamine
Related Note: 1495740310438
Rationale for change

Contents of the card are completely irrelevant to the tagged B&B video

Rejection reason

resolved manually

Text
Cyclophosphamide can be used as an immunosuppressant for the treatment of {{c1::lupus}} nephritis, as well as for systemic {{c2::vasculitides}}
Extra
- e.g., eosinophilic granulomatosis with polyangiitis (EGPA), microscopic polyangiitis, Henoch-Schönlein purpura, granulomatosis with polyangiitis (GPA), polyarteritis nodosa

- When given for vasculitides, often given with corticosteroids
Lecture Notes
Empty field
Missed Questions
Empty field
Pathoma
Empty field
Boards and Beyond
Empty field
First Aid
Sketchy


Watch Alkylating Agents
Sketchy 2






Watch Glomerulonephritis SOAP



Watch Systemic Lupus Erythematosus SOAP
Sketchy Extra
Empty field
Picmonic
Empty field
Pixorize

Physeo

Bootcamp
Watch associated Bootcamp video - Cellular Injury and Neoplasia: Cell Cycle Independent Drug Targets Watch associated Bootcamp video - Principles of Oncology and Therapeutics: Cell Cycle Independent Drug Targets
OME

Additional Resources
Empty field
One by one
Empty field
Changed Tags
#AK_Step1_v12::#B&B::08_Endocrinology::04_Repro::01_Repro_Hormones #AK_Step1_v12::#OME_banner::Clinical::07_Endocrinology
#AK_Step1_v12::#FirstAid::10_Hematology_Oncology::05_Pharm::13_Alkylating_Agents #AK_Step2_v12::#SketchyIM::04_Nephrology_&_Urology::01_Nephrology::02_Glomerulonephritis_SOAP #AK_Original_Decks::Step_1::Zanki_Pharmacology #AK_Step1_v12::^Other::^EXPN #AK_Step1_v12::#FirstAid::10_Hematology_Oncology::05_Pharm::13_Alkylating_Agents::Cyclophosphamide !AK_UpdateTags::Step1decks::Zanki-Pharmacology #AK_Step1_v12::#SketchyPharm::08_Antineoplastics::02_DNA_&_Cellular_Division::01_Alkylating_Agents::zanki_extra #PANCE::EOR::IM #AK_Step1_v12::#AMBOSS::Mx0MCR #AK_Step1_v12::#Physeo::09_Pharm::17_Hem/Onc_Pharm::11_Busulfan_Cyclophosphamide_Ifosfamide_Nitorsureas #AK_Step1_v12::#Pixorize::01_Biochemistry::13_Vasculitides::08_Microscopic_Polyangiitis #AK_Step1_v12::#OME::Clinical::Intern_Bootcamp #AK_Step1_v12::#Physeo::^physeo_image_update #AK_Step1_v12::#Bootcamp::Pathology::02_Cellular_Injury_&_Neoplasia::11_Cell_Cycle_Independent_Drug_Targets #AK_Step1_v12::^Other::^HighYield::2-RelativelyHighYield #AK_Step1_v12::#B&B::11_Hematology::04_Cancer_Drugs::02_Alkylating_Agents #AK_Step2_v12::#AMBOSS::mx0VCR #AK_Step1_v12::#Pixorize::01_Biochemistry::13_Vasculitides::06_Granulomatosis_with_Polyangiitis #AK_Step2_v12::#SketchyIM::07_Rheumatology::02_Systemic_Rheumatic_Diseases::01_SLE_SOAP #AK_Step1_v12::#Pixorize::03_Pharmacology::12_Oncology_Pharm::08_Cyclophosphamide/Ifosfamide #AK_Step1_v12::#Bootcamp::Hematology_and_Oncology::08_Principles_of_Oncology_and_Therapeutics::11_Cell_Cycle_Independent_Drug_Targets